



COMPANY OVERVIEW

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease. We are developing a first in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the field of cardiovascular disease, among other fields. Our goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs and bring these products to market to benefit patients, the medical community and our shareholders. Our current product candidates include three developmental treatments for ischemic diseases based on our CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation (a Japanese regulatory status that is similar in certain respects to "breakthrough therapy" designation granted by the U.S. Food and Drug Administration (the "FDA") to eligible investigational treatments) and eligible for early conditional approval in Japan for the treatment of critical limb ischemia ("CLI") based on the results of an ongoing clinical trial; CLBS16, in a Phase 2 proof-of-concept clinical trial in the U.S. for the treatment of coronary microvascular dysfunction ("CMD"); and CLBS14, an RMAT designated therapy for which we have finalized with the FDA a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina ("NORDA").

INVESTMENT HIGHLIGHTS

-  CD34+ cell therapy platform company with an advanced clinical pipeline with two programs with cell therapy "breakthrough" designation
-  Proprietary field-leading technology in multi-billion dollar global indications backed by a strong IP portfolio
-  Multiple potential value creating events in the next 12 months based on development milestones across the pipeline
-  Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience
-  Strong balance sheet; \$25.2 million in cash (December 31, 2019) with no debt and cash runway projected through 2Q 2021

C-SUITE LEADERSHIP TEAM

David Mazzo, PhD
*President and
Chief Executive Officer*

Douglas Losordo, MD
*Executive Vice President,
Global Head of R&D, and
Chief Medical Officer*

Joseph Talamo, CPA, MBA
*Senior Vice President and
Chief Financial Officer*

MARKET SNAPSHOT

Ticker Symbol	CLBS
Exchange	NASDAQ
52-Week Price Range	\$2.00 - \$4.20
Shares Outstanding (12/31/19)	10.5 million
Cash & Investments (12/31/19)	\$25.2 million
Fiscal Year-End	December 31

POTENTIAL VALUE CREATING MILESTONES



 1Q 2020	Complete Phase 2 enrollment in CLBS12
 1H 2020	Present full ESCaPE-CMD Data
 2H 2020	J-NDA Rolling Submission Initiation
 Mid 2020	Initiation of CLBS16 Phase 2 trial
 YE 2020 / Early 2021	Announce Phase 2 CLBS12 top-line data

CD34+ CELL THERAPY PIPELINE

Product	Indication	Development Stage	Commercialization Target
CLBS12	CLI	Registration eligible trial (<i>Japan; ongoing</i>)	2021
CLBS16	CMD	Phase 2 (<i>USA; start target mid 2020</i>)	TBD
CLBS14	NORDA	Phase 3 confirmatory (<i>USA; initiation pending funding</i>)	TBD

CD34+ CELL THERAPY PLATFORM

- Naturally occurring vascular repair (endothelial progenitor) cell
- Provokes restorative angiogenesis of the microvasculature
- CD34+ cells re-establish blood flow to under-perfused tissues
- CD34 is a cell surface protein that identifies a subset of mononuclear cells in the bone marrow and circulation
- CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius' proprietary platform technology selects and delivers a potent, concentrated population of the patient's own CD34+ cells for optimal therapeutic benefit.



- G-CSF mobilization eliminates need for surgical bone marrow aspiration
- No genetic manipulation or expansion of cells
- Four days or less from donation to treatment
- Cost-of-goods an order of magnitude less expensive than CAR-T therapies

CALADRIUS BIOSCIENCES, INC.
www.caladrius.com

CORPORATE HEADQUARTERS
 110 Allen Road, 2nd Floor
 Basking Ridge, NJ 07920
 Tel: 908.842.0100

INVESTOR RELATIONS CONTACT
 John D. Menditto
 Tel: 908.842.0084
 Email: jmenditto@caladrius.com